Avolynt, Inc.

More action is in store in the competitive diabetes segment in India, with Glenmark Pharmaceuticals Ltd. now readying a fixed-dose combination (FDC) of the sodium glucose co-transporter-2 (SGLT2) in

2019 saw Indian firms chisel and recalibrate operations, divesting businesses in some markets alongside striking niche deals to acquire assets and brands. Both private equity players and established f

IN VITRO DIAGNOSTICS Mergers & Acquisitions HalioDx Qiagen NV Qiagen Marseille SA Management of Qiagen NV division Qiagen Marseille SA have formed a new company, HalioDx , through a buy-out

With Wall Street estimating that non-alcoholic steatohepatitis (NASH) could become up to a $40 billion worldwide market in the next 15 years, it’s no surprise that an indication lacking great name rec